For the Urologist by the Urologist: Essential Concepts in Managing mCRPC.

Slides:



Advertisements
Similar presentations
ASCO G.U Lawrence H. Einhorn.
Advertisements

Castrate-resistant prostate cancer (CRPC)
Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.
Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.
How should we sequence therapy? Dipartimento Scienze Radiologiche, Oncologiche e Anatomo Patologiche; Oncologia B. “Sapienza” Università di Roma Enrico.
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Graph paper template R2 이지훈 / Prof. 맹치훈 Lancet Oncol 2012; 13:
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.
Sipuleucel-T Survival Benefit
Sequencing Considerations After Progression Following Initial Therapy for mCRPC mCRPC, metastatic castration-resistant prostate cancer.
Triple-Negative and BRCA-Mutated Metastatic Breast Cancer
METHODS and STATISTICS
CCO Independent Conference Coverage
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Applying the New Multiple Sclerosis Guidelines to Clinical Practice
The future of our patients already treated with first line chemotherapy First of all, I would like to take this opportunity to thank the Mediterranean.
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.
CCO Independent Conference Coverage
WHEN IS CHEMOTHERAPY INDICATED FOR HORMONE-NAÏVE PROSTATE CANCER
Novel Regimens and Considerations in Radionuclide Therapy for mCRPC
Updates and Insights on the Medical Science of Prostate Cancer
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
SYSTEMIC THERAPY OF PROSTATE CANCER
Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer
Perspectives on Triple-Negative Breast Cancer
Improving Survival in Glioblastoma Multiforme
The Challenge of Bone-Metastatic PC
Advanced NSCLC Without Actionable Mutations
BRCA, HRR Deficiency, and PARP Inhibitors
New Patient Journeys in Non-small cell lung cancer
Progression After Cancer Immunotherapy in Advanced NSCLC
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
Optimizing the Treatment of Recurrent/Metastatic SCCHN
A patient’s view on mCRPC What to tell our fellow patients!
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.
PARP Inhibitors and Cancer: What Do You Need to Know?
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Managing gBRCA-Positive Metastatic Breast Cancer
Treating mRCC After Initial Antiangiogenic Therapy:
Volume 66, Issue 3, Pages (September 2014)
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Maintenance Therapy in Advanced Ovarian Cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Practical Guidance on the Management of Pan-Negative NSCLC
Volume 71, Issue 4, Pages (April 2017)
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Targeting the Androgen Pathway: Current Best Practice and Future Directions.
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
New Paradigms in M0 CRPC.
CDK4/6 Inhibitors.
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Evaluating the Totality of Evidence
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Clinical Focus.
The Nurse View.
Possible outcomes of therapeutic treatments using the spiral model.
Uncovering the Right Sequence
Presentation transcript:

For the Urologist by the Urologist: Essential Concepts in Managing mCRPC

Goals

Case Study: Newly Diagnosed Low Volume Metastatic Disease

CHAARTED: Benefit of Docetaxel

Toxicity Grade 3 AE or Greater

Treating the Primary Tumor

Case Study, Continued

Abiraterone COU-AA-302 Trial

Enzalutamide PREVAIL Trial

Treatment Considerations: Use of Immunotherapy

Sipuleucel-T

Treatment Considerations: Abiraterone vs Enzalutamide

Case Study: mCRPC Progressing Through Second Generation Androgen Axis Inhibitors

Further Treatment Considerations

Emerging Biomarkers

Biomarkers: Mutations of DNA Repair and High Rate of Response to Olaparib

Cabazitaxel

Conclusions

Remaining Questions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.